XXII 78 2013

$FKLHYHir

/HYHPLUi

/HYHPLUi

42//HYHPLUi

/HYHPLUi

,QVXOLQGHWHPLU8PO)OH[3HQi /HYHPLUi /HYHPLUi H /HYHPLUi /HYHPLUi/HYHPLUi/HYHPLUi/HYHPLUi /HYHPLUi

/HYHPLUi $R H i

1RYR1RUGLVN $6 '. %DJVYDHUG 'HQPDUN 1RYR1RUGLVN3URGXFWLRQ6$6&KDUWUHV)UDQFH

'

ZZZQRYRQRUGLVNFRPZZZOHYHPLUFRP

1. Blonde L. et al. Patient directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets the TITRATE Study. Diabetes, Obesity and Metabolism 2009;11:623631. 2. Hermansen K. et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29(6):1269 1274. 3. Levemir EU Summary of Product Characteristics. 4. Philis-Tsimikas A. et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clinical Therapeutics 2006; 28(10):15691581. 5. Rosenstock J. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408416. 6. IMS Worldwide Data Q2 2009. 7. Reimer T. et al. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. Clinical Therapeutics 2008;30(12):22522262. 8. Home P. et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011 Dec;94(3):352-63 9. Shah S. et al. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study. Diabetes Res Clin Pract. 2011 Dec;94(3):364-70. 10. Litwak L. et al. Improved glycaemic control after transferring basal insulin from glargine to detemir in type 2 diabetes: subgroup analyses of A1chieve. IDF 2011 21th World Congress Abstract Book. IDF: Dubai, 2011; p 382-3 (Poster P-1151).

$FKLHYHi

iULPHHY/

GHW,QVXOLQ/HYHPLUi)OH[3HQi

/HYHP

i

PO8WHPLU

HPLUi

/HYHPLUi

H$R

/HYHP/HYHPLUi

/HYHPLUi

/HYHPLUi

/HYHPLUi/HYHPLUi

/HYHP

HPLU

PLUi

i

%'.$61RUGLVN1RUGLVN3URGXFWLRQ6$6&

1RYR1RYR'HQPDUN%DJVYDHUG

&KDUWUHV)UDQFH

1. Blonde L. et al taed titrtect dirtiena. P2009;11:623631. 2. .KmansenHer et a

eares CetiabD 2006;29(6):1269 1274. 3.esype 2 diabetolled ttronc heal TClinicca

diabe2ype twithpeople einsulin-naivedandomize in a ry devicerinsulin deliv

o insuinning or changed tes begdiabetype 2 diabetapies in people with tther

oup ares: subgype 2 diabetemir in tdet

ZZZ

daily ba-ecaemic goals using a oncor achieving glytion ffoal ialtrget-taro-tteatr, allelpar, edandomizr, eekw26-A.3. emirevL .isticsertact Charoducry of P EU Summar 4.

seuticaperra 2006; 28(10):15691581. 5. .ock JosenstR et a.eset gia oloetiabD 2008;51:408416. 6. ldwideorWIMS

ts wittiener handling study in pavosso, cr, open-labeldhe A1Ties:trounn cerestWy in non-apulin analogue ther

.tional studyave obserom the A1chievesults fres: R iDess Arongld CorWe. IDF 2011 21th ses of A1chievanaly

'

QRYRQRUGLVNFRPZZZOHYHPLUFRP

t faenero diffffewt of tasal insulin analogue: an assessmenonadd-asinsulinNPHwithemirdetinsulining omparc

as A.simikThilis--TP et al daily insul-eison of oncompar. Cal omparial cget tr-taro-ttea, treekw, 52-andomised. A r

2009.Q2 taDa 7. .TeimerR .alet tioinstruc,enesstuitivnI.esype 2 diabetth t seuticapherral TClinicc 2008;30(12):225

.e studychiev t.acrraes Res Clin PPretiabD ec;94(3):352011 Dt. acrraPClinResesetiab ec;94(3):364-70.2011 D 10. akwLit

-1151er Postubai, 2011; p 382-3 (P: D. IDFookt BacbstrA

.tudyTE SAATTITRgets theose tarasting plasma gluc iaDeinsulin-naivindrugs ingerw-looseglucalorotyaptheraimen of orego a remir with NPH insulin added tlin det

ine when addedgemir with insulin glaring insulin detrdinsulinefilledpraofeeptanccacttienpaand,timeon

522262. 8. .Home PP. .et al verttional non-inavn obserA52-63 9. Shah S. et al e assy of liffets in qualitemenvompr. Ik L. .alet ing reransffeer trtol affttroncaemic ced glyvomprI).

olismy and Metabesitb, Oess,etab.esdiabet2ypetwithpeople e

lytidiabetic drugs in pooral aning drugs inerw-looseo gluct

eusableraandedevicy erdelivtional study of people withen

ed with insulin analoguetsociaoine tgom glarbasal insulin fr

12

16 : M 1 1,08

18 :

22

24

00249 . , .

( 2 )

00251 - -

38

30

34 -

46 - 2013 - 10 2012

40 : ?

54 - 16

8

:

4 2013

5 2013

. -

Vox medici

. - , , - . j

, -, - .

Vox medici, - , - , , , - .

- . : , - - 2007 . 31.12.2012 , , , , - .

2012 .

.

Vox medici , , .

, . - - .

, - , , - , - , . - - .

, , Voxmedici, - . - .

6 2013

2000

. . 3 -1000 /: 02/3124-066; : 02/3239-060

: 200-0000114640-34 :

: 4030991274058;

e-mail: nachamed@mt.net.mk

lkm@lkm.org.mk www.lkm.org.mk

voxmedici@lkm.org.mk

-

. -

- - -

- -

- - - -

- - -

-

. -

. -

. -

-

- -

- -- -

. - -

. - - - -

- a- -

. -

, : 6.950

ISSN 1409-8865

10mg, 20mg, 40mg

8 2013

- , , , , , - , , - . , , 5.500 - -.

- - a - - -, , - - . - .

- a . - . - - - ,, - . - - , a ja

, 45 - , . , - . ( 2014 .) -, . , , . - .

, , - -, . - - 500 , - , - - 500 - , a .

- , , , . , 100 . , -

9 2013 2013

, , , . - , . - , , - , - ( - - ). - , , - , , - .

, . . , . - 4.000 ( - ) - : - , / , , , -, , - . 60% - - . - , - , - - .

. - . - ,

-. - , . , -, - .

, - , -. -, 1 , 1 , ( 1 , , . -

- -

.

-, , . - , , . , , - , - - . - - - , , .

, a - . , . - , - , . - , - .

- .

10 2013

, , . , . , . - ( - ) 20% , . - - , , , . 10% .

- , , -, , - , , . - American Medical Association Physician RecognitionAward European Accreditation Council forContinuous Medical Education. - , . - -, - -, - , , , (-

). - / . . , - - , - , - , , -, . .

- - , - . .

- 2013 , , - -, . , . , . - . - , - , , - , . ( -

,

,

11 2013

) , - . - - , . - - () ().

. , - . - - .

Vox medici

-, , , - . - - . , . , , - .

, , - - . - . , ...

1991 -: , , , - . . . , . -, , - , . . -. - , .

, . ,

- , , , , . , - . , -. ... , , . . , . - . , . , , , - ... -, - , - - . / . ( ), ( ). (- ) , .

, - , , -, , - , , , . , . - , - , .

. - , :

12 2013

- - . - , 27 , . - - . , , . - - , - - , , , - , , . , - , , - .

- - , . - - , - : - , , ..., , , - (EuropeanHigher Education Area EHEA EuropeanResearch Area ERA).

,

, , , - -, .

- - -, - , , . - . , , - -, - . - -, - - . - . , - , , - , .

, - , , , . - . , - , - - .

-

. -

-

,

,

,

:

,

,

...

13 2013

, - . , - . , .

- , . - . - -- . - , - (FP7, UNESCO, NATO Science for Peace,IAEA, .). , - -, , - . , , - - .

, - . - , - - - . , , , - . - , - , , . -

ed.macedonia 2012 , .

-, - . , , - .

- ( - ). -, - . - . (Erasmus mundus, Basileus, JOIEUSEE, Sigma). 2011-2015 - ERAWEB (Erasmus Mundus-Western Balkans) , - .

, - -, - -. -

,

- ,

14 2013

, ( , - , , ...) - , - . - ( FP, CEEPUS, JRC), , - . - .

. - - : - ( - ), a , - , - - - , - ... - , , -. - - - - , . , - - (.. lump-sum), - - .

- (- , ), - -, , - ...

, International virtuel E-hospital foundation (USA) , , online -, , .

- - - , - .

. - -, .

-, - - , - ( , -, ..). , - , - , ( ). , , , - -- . . -, , - , .

, - . - .

Vox medici

International virtuelE-hospital founda-

tion (USA)

t***tt***t

x mg mg

R

16 2013

, -, - , 0-18 ; 19-65 65 1 18-65 , 1,3 0-18 1,4 65 . - . . ( - 6 , - , , , ...), 2,9 ( 90 ). - , - 15 . - 1 1,08 , - , - . , , ,

- - - , , - -, - - - .

- . - .

, , -

, 8 - . - , - , - .

, -, - , . , -

M 1 1,08

,

17

. , - . , - 1.000 , (), ( ), .

, , - - - . , - .

- - - (). - - :; - ; -; 2;- - ; - ; - .

-

2013

- , - ( ,, 4 ...) - , . - . , - , - - , - - .

, () 15 , - . , , - , , . - , 3 4 , , 1.000 1.200 -. , 300 400 . 20 . ( -) ,

. 6.000 8.000 . , . , , - . . , , , . , , .

M

3 4 , ,

1.000 1.200

,

18 2013

- - , . - (K) - - c- , , , .

, - (, , ). (1).

. 68% - 64% - . (51% . 31%), , - .(1,2)

- (3).

: ,

, , - ; ; ; , .

: , , ,, , .

: - , , , - .

: ,

, , - , , , .

: - , - , , , ,, K.(3)

-, - . , . :1. 2. - - , , . (4)

- :

. - : ( , -

:

(K)

:/,

19 2013

) . status cos-meticus - .

: 15-20% , , - .

: 25% . (4)

- .

: - , - .

: 40% - , - , , , -, - , . -, - , . -, Sodium Laureth Sulfate(SLS) Ph .

: - . (5)

K , - K - , .

(, , ) ( ). - .

, ,

patch photopatch - . 3 - : - ( ), - (- ), ( ).

Stinging ( ), Kligman Frosch 1970 ., . - -, . - . - -

; ; ; -

;

( , ; -

, ;

- ;

;

- - ,, ;

, ;

, , ;

, - ;

3 6- , ;

;

.

Pons-Guiraud:

(7)

20 2013

- 4 .(6)

.

. - - -, , - .

- , . - TRPV1 (Trans-4-ert-butylcyclohexanol), - lysate, Bifidobacterium lon-gum spp.,

low-level laser/light .(6,7)

1. Willis CM, Shaw S, Lacharriere OD, Baverel M,Reiche L, Jourdain R, et al. Sensitive skin: An epi-demiological study. Br J Dermatol 2001;145:258-63.

2. Misery L, Sibaud V, Ambronati M, Macy G,Boussetta S, Taieb C. Sensitive scalp: Does thiscondition exist? An epidemiological study. ContactDermatitis 2008;58:234-8.

3. S.M. Wilkinson, M.H.Beck. Contact dermatitisirritantI, In: RooksTextbook of Dermatology, 8thedn,Vol 2, 2010: 1072-1089

4. Primavera G, Beradesca E. Sensitive skin:Mechanisms and diagnosis. Int J Cosmet Sci2005;27:1-10.

5. Farage MA. How do perceptionsof sensitive skin differ at different anatomical sites?An epidemiological study. Clin Exp Dermatol. 2009Dec; 34(8):e521-30.

6. Inamadar AC, Palit A. Sensitive skin: an overview.Indian J Dermatol Venereol Leprol. 2013 Jan-Feb;79(1):9-16.

7. Pons-Guiraud A. Sensitive skin: A complex andMultifactorial syndrome. J Cosmet Dermatol2005;3:145-8.

. , . , . , . , ,

-

. SMARCAD1. , adermatoglyphia, , . , - , . 2007 - - , .

- , , - -

. , , - SMAR-CAD1. - ,

, - . , SMAR-CAD1, . .

Rinoco

DOZIRAWE:

Rinoco 50 g : a . 50 . : (), , , , , -80, .

50 g 120 . 50 g 50 .

. - - . . ( , ) ( , ). 4 . - () . : ; ; ; . - , , : - ( , )- HIV ( , ). - . , . ( ), . - , , . - , ; . - ; ( ) . -; ; . -; - 25 . - .

22 2013 2013

, ,, , , . , , , . - , . .

, 1995 11,5 , 2003 23,1 . - .

, .

- . . , - - ( ) .

- , , - , - .

- -, -, , , (10),

, , , , . - , - , . - .

. - - . , . , , , , - , - , ,

, -

, , ,

(10), ,

,

,...

23 2013

. . -, , .

, . -, - - .

, - . .

, . , . 50 - .

- . - . :, , . , .

, . , , , ...

, , .

, -. , , , .

. . - .

- , - , , .. .

. , . , . , .

. , - , , ,, . , ,. -- . , , . .

. -

,

- -.

,

24 2013 2013

, , -, , ., , - .

- , - , - . . -. - - , (orbitofrontal cortex) -, .

, - , . - , . - , . , - .

- - , - . , , . -

- , , - .

, , :

, , .

, . ,, , . , - .

. : - , . , , . . - - , -

,

,

25 2013 2013

- , -.

- . The Neurocritic, - . , - , .

, - - : , , . - --. 21 , - . , - 18- 9-- .

, 2009 - Archives of General Psychiatry,

- 18-- -.

(: Bild Zeitung)

- 21. , 1,2 . 200 80 - - -. - HPB Human Brain Project( ) , -, , , -, , - .

, . , - , - .

, , , HPB .

- - - , , .

- , - - , . , - . . -, . , - - - , .

1,2

26 2013

- . , , - - .

- Roche . - - Roche - .

,

, . , , - - . , - - . - . -

-

. -

-. - ( 2,9% -). . 2/3 , - -

- .

Roche .

- - - . - - -

. -

, - -. -. - , - .

-

Penzberg

UtsunomiyaUkima

Basel

San Francisco Vacaville

Singapore

Oceanside

Roche: Roche 2011 Finance Report

2.9 %

66 %

: Verband der Diagnostica-Industrie

6.720.000.00080.129

12218

1

27 2013

- . 12 - . 7,6 - . Roche - . 28 . - - , - - - . - .

- , - . , - -. 40 - . .

- - - Herceptin. Roche Kadcyla. Roche -

- - .

Roche Kadcyla .Kadcyla - HER2-- . - , 30- Roche Genentech HER2 Roche HER2- ..

Herceptin, Kadcyla HER2- , . Kadcyla - , - , DM1 .

, Kadcyla -. - trastu-zumab (Herceptin) , .

Roche 25- - , 8 I II . Roche - - .

2012, - Perjeta (pertuzu-mab) Herceptin(trastuzumab). HER2 2 . - HER2 , - .

-. 10 - 22 - . 58 . -

Roche - . Roche, 116 - Roche, -, , - , - , - .

Hoffmann-La Roche Ltd.

:

www.roche.mk

28 2013

, , - , ... . - , .

, - . - , . - . , , - , .

, - .

-, , 20 , - . - .

, 19 - , . , , - . , , (- ) . - , - , -. - .

. 10 , - , : , - , , ... - , , .

, - , - , , , - . - - 2011 2015 , ().

,

30 2013 2013

VOX MEDICI: 2011 , - . ?

, - , , (). - , . - -. , , . , , - /. - - 10 - (Dr. Cointault, Dr.Nogier, Dr. Lavayssire). . () 18 . - . , ,, , -. 2011 - () - 181 , 38 , 8 -/ 9 , . . 2012 : 171 , 28 , 7 / 6 - . 2012 .

VOX MEDICI: ? , , -?

, - . , 3 , 1.000 . , - . 474 - ( CRISTAL). - , - 33 2011 34 2012, - - - - (). 24 . - , 30 . , ( 60 / 50 55 - / / - / - > 15/). , - CRISTAL - . , . , , :

-

-,

- -

-

. D-R LIONEL ROSTAING -

31 2013

1.

- . , - , . , , . (- ) -. (DrLaure Esposito), (Prof.Dr. Federico Sallusto), -, , , , , . , , - (-, , de novo, , ). , , . , : , , - . - -, - . - - . , () 3.000, , 3.000 -. , - , - . , , - .

2.

, - , - . -, - (), - . 3.000 - 375/2 -0 -8. 3000, - , . - IV (20 -0 -4), , . 8-12/ , 5-8/. 1, 2 - 15, 500 2 . - 10//, - 2// -1, 1// -2, 0.5// -3 10/ -45 5/ -90. - , - . , () 7 . , - 15, 30, 60, , 6 . - 10 15%. . - , . - / 400 6 ., , 500/, 2 . 1, 2, 3, 6, 9 12 .

-

32 2013

3.

2010 -, - . , - (- -). 1/120, . - Tyden T et al.[Transplantation. 2007; 84(12 Suppl):S44-7]. 30 , -, - - (Glycosorb ABO, Glycorex) - (Immunosorba, Fresenius). 1/10 . , - - , . 10 , . . 10%, - . - , - , (). . , -, < 6/ - (1/) , - . - 10- , 3-, 6- 12- .

VOX MEDICI: ? , ?

, 1.610 . . - . - , -- - , - - - -

. -. 50% -- , - . - , , , - , . , , - 7 - ( 4 ) -, 6 . - 5 9 19. , - , - - - - . - , . , . , , - 1-1,5 - . - .

VOX MEDICI: - ?

. -. , , - 4 . , - , , - . , - , - , . - , , . . -

- , - . , - . - , - , . -. - : () ( ) . , . , , , - . , -, , . - . , , , , , , . , , , .

VOX MEDICI: ?

. , - , . . - , - . .- . - . . 2012 2 , .

VOX MEDICI: ?

- . , ( , - , - ). , ( ) - - . , - - ( ). , - - , . , -, . , , , , , . - . . , - .

Vox medici

33 2013

- - - (). -

, , . - - - - . - - .

() - , de novo . , - . , . , - . , , . .

- . , - / . - -

, . -. - , - - , - - . - .

: , - , 2. , , , . - - , 2.6% 22.9% , .

- . . - , . , , - . , . - , 6 -.

34 2013

-

,

- , - - () - - . , - . , ( ), - -, , - . , - ( , , - .). , . - .

Kalantar-Zadeh . 13.664 . , - . - - - . - - - - .

-

, - - (-) .

-, -. 1 2 ( ). 3, 4 5, -, , . -, .

, , . - , , 50 /. 21-64%. ( 1) , - , - 200 / - . - , -. , AASLD (American Association forthe study of the liver) -2 135 mcg , -2b 1 g/. -2 180 mcg , -2b (Cornberg 2002). , - -2b . , --2 .

- -. - () - , -

,

35 2013

1.

* ** 38% 12

36 2013

, de novo . , , -, - .

, ., , - . . - -. - . - de novo -, - , . , - . , - , .

5 -, - - ., ( 10-), - - . - - -. , - . - - , - .

-

. , - , - - . - 9 100%, 0.3 8 . , . . , - . , - . , - ( . - , - ).

37 2013

, 6 - , 3 . - -, - . - , - - . - -- , - . , .

- - . - - , - , - . - - - -.

1. Ghany , Strader DB, Thomas DL, Seeff LB.Diagnosis, Management, and Treatment ofHepatitis C- An Update. Hepatology 2009; 49,4:1336-1374

2. Clinical Practice Guidelines for the Diagnosis,Prevention and Management of Hepatitis C inCKD: www.kdigo.org

3. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH,Lian JC. Long-term impact of hepatitis B, C virusinfection on renal transplantation. Am J Nephrol2001;21:300-306.

4. Aroldi A, Lampertico P, Montagnino G, PasseriniP, Villa M, Campise MR, et al. Natural history ofhepatitis B and C in renal allograft recipients.Transplantation 2005;79:1132-1136.

5. Furusyo N, Hayashi J, Kanamoto-Tanaka Y,Ariyama I, Etoh Y, Shigematsu M, et al. Liverdamage in hemodialysis patients with hepatitis Cvirus viremia: a prospective 10-year study. DigDis Sci 2000;45:2221-2228.

6. EASL Clinical Practice Guidelines: Managementof hepatitis C virus infection. Journal ofHepatology 2011; 55:245264.

-

, 31 2012 , .

. - , - - - - , , , , -

. . - - .

. , .. , -, (-, ), -, . , - .

- : ( ), - / -, , - (- ).

, , . - .

- - - .

,

38 2013

- - , . - . , , . , , - .

- 12 ( 1985 2008) , , - , -. 116.056 ( 17 70 ) - , -. , , - , -, , - , (BMI), , , - . 12.

: - , - , , - .

- - (HR=1.16, 95%CI 0.90-1.48), (HR=1.17, CI 0.88-1.54),

(HR=0.97, 95%CI 0.82-1.14) (HR=0.86, 95%CI 0.68-1.09). - , - , - . , (BMJ 2013; 346:f165doi:10.1136/bmj.f165).

- - , . - 15. - - - - .

- -- - , 100 . , - - , . - , - , , . , 40-60% - - , - . , . - , , , ., - , (PLoS Med 2013;10:e1001388).

- . , ? , - - . - , . a ( ) (- ).

2.767 , , . , , HIV. 60% - , 50% , 50% . - 2 3 .

- . - - , (88.7% 90.9% , 85,1% ), - (4.8% 4.1% 7.1% ). - , . (N Engl J Med2013; 368: 425-35)

QT -

38.397 - . - re-uptake , ,, , (-

39 2013

, , ),, -. , , - , QT . - - QT (

40 2013

, , , , . - VI- - , , - ().

, , , , - . - , . a , , .

, 21 11 , .

, , , , , - . , .

, - , , . 17 - . .

, - . - , .

60 , 2011. , .

- 90 ( ) , , - - . - , . -

?

:

41 2013

- , , - (-) - .

2011 382 , . - , 65 %, 30 . -. -, .

, -, - . , - , , - . .

, . , 80. ,

. 22 51. - 3,3 , , , 100.000 . , , CT. - .

. 10.000 - , -. - 10.000 , . - -. - , 100.000 ( - ).

- - - -- () . 2007, - , . - , , - , 17 . - , - 5.000 , , , 1.280 .

, - , , .

, - , , .,

,

,

...

42 2013

. - , () , , , . - , , , .

, , . , 15 - .

- . - , .

, - - - . 80

, , . , - - . - - , - - , .

- , - , ., , . . , , . , , .

. - , - . , , - , - . - -, , - . 1,7 , , 10% .

,

15

-

43 2013

- 17 1992 . 21 , - . , , - - , , , ... , - , - VIIa .

1923 , , . 90 - . . : -VIIa , (/ ).

15.2.2013 , - 20 - 90 -

. 150 , - -. , . - , . - VIIa -, - . - .- , - , -, .- , NovoNordisk Health Care, VIIa . - -, , - , . , - - - .

-20 90

44 2013

-, - ( ) - . - - . 1966 , 1972 - Gottesman Shields. , , -. - 30 2000 , MEDLINE 16 , 2000 1586.

-, , , , . , , , . - : ) - ; ) ) . , ( ), . EEG

. , - (fMRI) - , attention deficit hyperactivity disorder (ADHD). EEG- ERP ( ) - .

- -,

, -

, - , - , - , - .

- , , , , - , , , ... - , -

- , - .

, , ... .

, , , , .

, .

: . - -

, (arousal)

o

o

ADHD

-

45 2013

. -

: -

, -

. -

, -

, -

3 .

, -

236mol/l, .

52 - , 2-3. - . : 170/105 mm Hg, , , - 3-4 ( 1 - ). , () . - : 73 g/l, 43mmol/l 796 mol/l, ++. ( 2 - ). (ANCA) , -. -. , . - ?

1. Mycosis fungoides2.

3.

4. 5.

: , ?

: (. , .43/12 145/12), 6.4.2012 , . 13 1 - . - . , - , . , (: , ). - . .81/12 .147/12. -. - . , - - ( 25 ) - - . , ( 316) -, , ( , . 38/91, 46/93, 55/95, 10/04, 84/05, 111/05, 65/06,5/07, 77/08, 67/09, 88/10, 44/11 53/11). 318 - . , , .

46 2013

. , (CCI) - :

(DBT) 3 -

. - , 3 . .

-

. , . - .

- - . - . -. - , .

-

, .

( - ) - , , - .

. . , . - - .

, .

2013

, .

, . , .

-

-.

- , , - . , .

2

- . - - - - 2.

47 2013

10.

, , . , . , .

9. -

: - , . - . , .

8.

- 80-90

, - , .

, 65 , . , .

TIME

10 2012

-

48 2013

,

7.

, - . 50 . - 2-3 . 50 . - - 3.500 - , - . , 30 , , .

6.

, . -. - 30.000 510 , . , - .

5.

, . , .

4.

. - . - - .

3. Truvada

. , . - - 42-57 .

2.

2012 , , . - . , 10 - . - - - .

1. 98 %

- - . , , - - . , .

, - , , ... , - , - , - . , , - , , - , - , - .

- . , , a , . ,

, , , -. , , - . -, o , -. - - , - . - , -

. , , - .

, , - . , , ,

49 2013

. -

, , , . - , -. - .

-

, - -

, , -

, - -

-,

-

-

. , - . - - .

- , . . - . , , , -, ... , , - . . , , , , . - , . - , ,, e , , . .

. , .

4-5 . - , -

. - . - , . . 10 . , , . - . -, , , - .

- . , - , .

50 2013

- . - . . , --, - . , - - ? ,, ... , - , - .

, . , - , , - . - , ,

, ... , . -, , , -. o -. - . , ., .. - .

e

, ,

, -, , , , ... - , , , . , .... . , - , . , , , .

, , -, . , , - , , - , . . ? . . , - , . - , , - , .

Vox medici

51 2013

. - -

- 1948- - , , . . - . , , . . , , ... ,, ... . 20 The Times are a chan-ging, - - .

, , - s , . . -, , -, . , . , , , , , , .

, . . . . 300 20- . . . , , . . , . , . . .

, , , , . ... , . .

. -

. . . . - . - . . . -, , . , .

52 2013

- -, - GA2LEN. - - , , , .

, , , , , - - . 18 - , 50 , 21 , , -, - . ,, . - , , , . - - , ,, , , -. .

- - . - , - - .

A

-, , -, . -

- - , , - . - -, - - . - , - .

412 . 14 : ,, , - , , - , - , , -, , , , -, Asperger , Rett , - - . e - - . . - .

, , - . , . - . . - , - . . - -, ... , , , -- .

53 2013

- - . . - ( ), ,a , -, , - . 400 , 37 75 , , , , , , .

(occupational health), , , - (occupational medicine) -- , , . : , , - , -... - -, , - , - .

- . , - , -. , - - . . , , , , ...

. -

- . - , - , . .

-: - - ; - ;- ; - ; - ; - ;- ; -- ; - - ; - .

, -, -, - . -- , / . , . , - - -, - , .

74 - -, . 10- - , . - - - . .

- . -

54 2013

, - (980-1037). . , , , , -. . , , , , , ...

- . , 16 . 16- . .

18. - . . . . , , .

Kanun fi al-Tibbanun - - . Canon medicinae . Kitabal- ifa ( ), Al-Advija al-Kalbijja ( ) Kitab al-Kulandz( ). , , ... 760 , -, , . - - . , .

, - . -

.

, , . 100 , , -, . (-) , . , , . , , .. (). (). - , (: emanatio - -, , ; emanare - ).

- 16

. , 16.

. 16-

.

Vox Medici 16, 2012

( 2 )

. , .

-

-

77 2012 Vox Medici 10 2013 . (02) 3 239 060 (02) 3 124 066

106

Vox Medici , , , . .

- , . , , . , , . , . ( ) ( ).

() : , , , , ,.

, , , . ( ), , , - .

Vox medici

Vox medici. 12.000 , - Vox medici. Vox medici 2013 .

. - -. .

:

.

:

- . . - . . - , . - , - .

. - : . . , .

:

, .

:

, , .

:

() - 1 : 4.000 . - (1).

- , (2).

:

1. I.V. , .

2. ( -) (4, 6).

(2).

(5).

:

1. - , - (3, 2). - - (3, 2).

2.

2013 00249

( 2 ) . , . -

. (4, 6).

: .

: - - .

22- , - . . . , , , - , (2, 3). - . propofol (-) leptosukcin ( ), fentanil () norkuron( ). - (anapartes)(4, 6). . , - ( - )(6).

. . 24- , . . . - - (2, 3). , , propofol leptosukcin, fentanil norkuron. (anapartes)(4, 6).

:

, . .

.

:

1. Obstetric Anaestthesia and Uncommon Disorders, edited byDavid R. Gambling - Cambridge University Press, 2008;

2. Anaesthetic Difficulties in Neurofibromatosis, by M.McDFisher, Anaesthesia vol. 30, issue 5, 2007;

3. Management of the Difficult and Failed Airway in ObstetricAnesthesia, by Gurinder M. Vasdev at all - Journal ofAnaesthesia, 2008, 22:38 - 48;

4. Anesteziologija, 1999 Beograd, urednik Prdrag Lalevic;5. Neurofibromatosis in Pregnancy, by Garden H. Swapp at

all, British Journal of Dermatology, 2006;6. Obstetric Anaesthesia, edited by David H. Chestnut, 2004, USA.

00250 2013

2013 00251

2008

.

: - . - , .

: - . , - .

: . 2008 23,94/100.000 , 2011 4,66/100.000 . - 2008 1774/100000 , 2011 154/100.000 . (= 0,98). (72,2%) - (27,8%). - 40-49 22,19% , 0-9 3,65% ) .

: .

: , , .

: - ,

, , - - - .

- . 1962 (3), 1963 (3 ), 1968 (1 -) 1979 (1 ) (1).

, , - 1980 112 , : 104 , 5 3 . 1985, 1986 (71 70 ) , 1992 (922) - 1980-2007 383 - 19,4 100.000 (1).

, 1997 ( , .). 8.000 (2).

. 2008 (-), - , , 59/2008 ( ) 46/2010 .

. - . (3).

-

. , , , - 1999-2009 953 949 514 (3).

, -. , , , - (4).

. 1.1.2008 31.12.2011 .

- , , . , .

.

, 32.286 -

. () - 2008 1.774 100.000, 2011 154 100.000 . 91,32% , 2011 2008 ( )( 1).

1. . 2008-2011

. 1.1.2008 31.12.2011 1.041 .

() 2008 23,94 100.000 , 2011 4,66 100.000 . ( .1). - 80,53%.

- ( = 0,98;

2013 00253

- 2,6 : 1 - 2,6 .

1.041 - , , 752 (72,2%) 289 (27,8%) ( 2).

- , -- - . .4 - , - , , , ( .3 .3).

2 2008-2011 . ( %)

. 4 2008-2011

, , - 40-49 231 - (22,19%), 0 9 38 (3,65%) ( 4).

. 5. 0 9 2008-2011

2008/ 2011

N 37 61 83 130 129 159 146 96 82 47 35 36

2008 2009 2010 2011 .. %

15 12 6 4 9,25 0,036 3,6 25 21 8 7 15,25 0,059 5,9 33 28 11 11 20,75 0,080 8,0 62 32 27 9 32,5 0,125 12,5 63 37 15 14 32,25 0,124 12,4 78 40 19 22 39,75 0,153 15,3 82 40 16 8 36,5 0,140 14,0 49 16 25 6 24,00 0,092 9,2 35 29 14 4 20,50 0,079 7,9 22 12 11 2 11,75 0,045 4,5 13 9 9 4 8,75 0,034 3,4 13 11 7 5 9,00 0,035 3,5

260,25

( % ) 0 - 9 38 3,65

10 - 19 104 9,99 20 - 29 159 15,27 30 - 39 177 17,00 40 - 49 231 22,19 50 - 59 186 17,87

60 146 14,03 1041 100

/ (%) 0 1 2,63 1 1 2,63 2 2 5,26 3 4 10,53 4 2 5,26 5 7 18,42 6 3 7,90

7-9 18 47,37 38 100

.3.

2008-2011 .

. 3 2008-2011 . ( )

00254 2013

0 9 . 5., -, ( .5)

2010 (8,18/100.000) (), 2010 0,07/100.000 , 0,86/100.000, 0,03/100.000 (5). . .

- 66,2 %, - 33,8% 1980-2009 (6)

72,2% , 27,8% .

1,96 (6) 2,6 , , - .

( ), , , 1980-2009 (6).

- 40-49 22,19% ,

. 1980-2009 20-29 (6), - - - 45-54 35-44 (7).

- , , (8).

-

- .

- - , - . -

- (, );

- , , - , .

- - .

1. .

, 2008-2009 . :http://www.iph.mk/index.php?option=com_content&view=article&id=138%3A-2008-2009-&catid=41%3Afrontcategory&lang=en. 30.04.2010

2. European Commision.DG SANCO..Report on the outcome on theEU co financed animal disease eradication and monitoring pro-grammes in the MS and the EU as a whole.Fianlreport.11.07.2011.page 138

3. Kirandziski T, Nikolovska G, Nakova E, Smilenovska B,Stojmanovska B, Naletoski I, et al. Brucellosis control in small rumi-nants in the Republic of Macedonia. Prilozi. 2010; 31(1):181-90.

4. Smallstock in Development. Brucellosis. Available at:http://www.smallstock.info/info/zoon/brucellosis.htm. Accessed:29April 2010

5. European Food Safety Authority, European Centre for DiseasePrevention and Control; The European Union Summary Report onTrends and Sources of Zoonoses, Zoonotic Agents and Food-borneOutbreaks in 2010; EFSA Journal 2012;10(3):2597.[442pp.]doi:10.2903/j.efsa.2012.2597.

Available online:www.efsa.europa.eu/efsajoural

6. Donev D, Karadzovski Z, Kasapinov B, Lazarevik V.Epidemiological and public health aspects of brucellosis in theRepublic of Macedonia. Prilozi. 2010;31(1):33-54.

7. . ,2007. 3. 103.

8. Mile Bosilkovski, Ljiljana Krteva, Marija Dimzova, Ivan Vidinic,Zaklina Sopova, Katerina Spasovska. Human Brucellosis inMacedonia 10 Years of Clinical Experience in Endemic Region.Croatian Medical Journal 2010; 51: 327-36

2013 00255

lkm@lkm.org.mk

http://www.lkm.org.mk

Vox Medici , , - . - . Vox Medici / -

1 -

4 (216 x 279 ) 25 , -, , 12 , Mac C Times, - Times New Roman. ( / / ) :

1. 12 6 / / ;

2. 8 4 - / / ;

3. - 6 3 / / .

- : , -, , , - , - . , .

- -: : () -, , ; () - , () - ; () ; () - -

() / , , , .

: - - - . - - . - : () - - ; () - ; () - . (), () () . - . - . - ( ) .

.

- : 150 250 ( : / , - , - , - , , -/ ( , -), . - .

:3-5 -

. Index Medicus - (MeSH); MeSH , - .

- : - - , , : , , .

: . - . - , - - / . - .

( - : , , , ... ...) : - . - - ( , -). , ( , -), , - . - , / -; , / , - , , - .

00256 2013

2013 00257

: , - - . - - - . , - ( - CI). - - , , - . ; - . - . - ( - ). - .

, ( ), , -, , . - , - .

: - . - . , - . . - , . - . - -

. , , .

: - - , - . , Index MedicusConsult list of Journals indexed inIndex Medicus( -).

- , . , - , - - .

: :

( - , , - ).

1. You CH, Lee KY, Chey RY,Menguy R. Electrogastrographic studyof patients njith unexplained nausea,bloating and vomiting. Gastroenterlogy2001; 79(2): 311-4.

2. Colson JH, Tamour NJJ. Sports

injuries and their treatment. 2nd ed.London: S. Paul, 2006.

: - , . -. 6 8 . , - . - . - , , - . - -.

: . - - , - . , - -, 127x173, 203x254 . , - - . - - , .

( , -...) - - , - - ( , ). , .

, , .

-

. . , .

-

- , , - .

, .

e , , . 10 mg, - (5 mg). 20 mg. , . . , 5 mg . , . , - . ( SSRI ): 18 . , - . , . , - . SSRI , . / , , . SSRI/SNRI . , . , ( , , - , , ), - , .

: , , - . : ( , ), ( ( , SSRI), ( , ), , ), , , . : , , , , , , , , -, , , , . / . . , , , , - , , , , , , , , , , , , , , , , , , , , , , , - , , , , , , , , , . . 28 -- 5, 10 20 mg.

: - , . - 1 .101, 1000 (02) 2720310, (02) 2700325, -: info.mk@krka.biz, www.krka.si

.

- 5 mg, 10 mg 20 mg

11/2

012,

, 2

012-

0017

764.

1 x 150 mg